Tonix Pharmaceuticals Holding Corp expected to post a loss of $2.93 a share - Earnings Preview

* Tonix Pharmaceuticals Holding Corp is expected to show a fall in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024

* The Chatham New Jersey-based company is expected to report a 22.7% decrease in revenue to $3.083 million from $3.99 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Tonix Pharmaceuticals Holding Corp is for a loss of $2.93 per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $11.00​, above​ its last closing price of $0.14. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jan. 1 0001 -1.23 -3.27 -19.28 Missed -489

Mar. 31 0001 -12.38 -12.48 -5.76 Beat 53.8

Dec. 31 2023 -55.70 -52.59 -27.52 Beat 47.7​

Sep. 30 2023 -47.04 -47.68 -58.56 Missed -22.8

​​Jan. -88.09 -88.16 -85.76 Beat 2.7

1 0001

Mar. 31 2023 -88.39 -97.00 -1.04 Missed -7.2​

hundred

Dec. 31 2022 -1.08 -1.72 -1.12 Beat 34.9

hundred hundred hundred

Jan. 1 0001 -1.96 -2.04 -1.38 Beat 32.4

hundred hundred hundred

This summary was machine generated November 6 at 13:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)